Just over a month into its search for “strategic options,” ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.

…read more

Source: ThromboGenics is picking between billion-dollar bids, report says


0 No comments